Last reviewed 2026-05-23 · How we verify

Etamin (TROLNITRATE)

Phase 2 active Small molecule ✓ Verified May 2026

Etamin (generic name: TROLNITRATE) is a Vasodilators Organic Nitrates drug. It is currently in Phase 2 development.

Etamin works by releasing nitric oxide, which relaxes blood vessel muscles and causes blood vessels to widen.

Etamin is a small molecule with the synonyms TROLNITRATE, TROLNITRATE, TROLNITRATO. It has been studied in a randomized controlled trial as part of an art education intervention, specifically cross-stitch training, to improve creativity and mindfulness in midwifery students.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TROLNITRATE
Drug class	Vasodilators Organic Nitrates
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

When nitric oxide is released, it signals the blood vessel muscles to relax, allowing the blood vessel to widen and improve blood flow. This can help to reduce blood pressure and alleviate symptoms of conditions such as angina. The widening of blood vessels also allows more oxygen and nutrients to reach the heart muscle.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Effects of Art Education on Midwifery Students' Imagination, Individual Creativity, and State Conscious Awareness (Mindfulness): A Randomized Controlled Trial (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Etamin CI brief — competitive landscape report
Etamin updates RSS · CI watch RSS

Frequently asked questions about Etamin

What is Etamin?

Etamin (TROLNITRATE) is a Vasodilators Organic Nitrates drug.

How does Etamin work?

Etamin works by releasing nitric oxide, which relaxes blood vessel muscles and causes blood vessels to widen.

What is the generic name of Etamin?

TROLNITRATE is the generic (nonproprietary) name of Etamin.

What drug class is Etamin in?

Etamin belongs to the Vasodilators Organic Nitrates class. See all Vasodilators Organic Nitrates drugs at /class/vasodilators-organic-nitrates.

What development phase is Etamin in?

Etamin is in Phase 2.

Drug class: All Vasodilators Organic Nitrates drugs
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing